Unilife is at it again. This time it's Novartis signing a deal with the injectable technology provider, adding to Unilife's impressive list of recent agreements with top pharmaceutical companies Sanofi, MedImmune and Hikma.
The ongoing shuffle-and-cut at AstraZeneca has two U.S. higher-ups headed for the exit. As the Washington Business Journal reports, the company's new specialty care unit will lose its top executive, Scott Carmer, and finance chief, Tim Gray.
Injectable drug delivery specialist Unilife joined forces with AstraZeneca's MedImmune this week to use Unilife's wearable devices with MedImmune's line of large molecules, putting both companies on the leading edge of a potentially profitable market.
The intense R&D focus in biopharma R&D circles on the therapeutic punch of cancer immunotherapies hasn't escaped the notice of top analysts, who are making some megablockbuster projections on the commercial impact these new drugs are likely to have.
AstraZeneca has struck a deal to buy one antibody-drug conjugate developer for up to $440 million while making a $20 million equity bet on another as it continues a global biotech shopping spree to stock its pipeline of cancer drugs.
AstraZeneca is rolling the dice on a $500 million deal--including $225 million upfront--to buy the early-stage cancer immunology specialist Amplimmune for its U.S. biologics arm MedImmune. AstraZeneca is promising up to $275 million in development milestones.
Sanofi and AstraZeneca's biotech unit, MedImmune, have begun shipping vaccines ahead of the fall flu season.
The 2013-14 flu season is set to be the most closely watched in years. In February, FDA cleared the use of quadrivalent vaccines which protect against two A and two B strains. GlaxoSmithKline and AstraZeneca began gearing up, and Sanofi will now join them too.
AstraZeneca's announcement early this year that Peter Greenleaf would be "promoted" from the head of MedImmune to the top job in the company's big Latin American division raised a few eyebrows around the industry.
Last year AstraZeneca's MedImmune did about 20 biologics deals, not counting the academic pacts it assembled. Bahija Jallal, head of R&D, tells FierceBiotech there will be no letup in talent scouting: "If we do as little or more than last year, I would be happy."